Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

3

SEC Filing Details

Document Details

Form
Filing Date
Apr 26, 2018
Document Date
Apr 16, 2018
Form Description
Initial filing by director officer or owner of more than ten percent.
Filing Group
3,4,5
Company
Stemline Therapeutics
Issuer
STEMLINE THERAPEUTICS INC
Filer
HUME DANIEL


Copyright 2018 - Stemline Therapeutics, Inc. All rights reserved